Ocugen to Participate in Upcoming July Industry Conferences
Rhea-AI Summary
Ocugen (NASDAQ:OCGN) will participate in several ophthalmology-focused conferences in July 2026, highlighting its modifier gene therapy platform and retinal disease programs.
Events include Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and ASRS presentations featuring OCU410 Phase 2 ArMaDa 1-year results and Phase 1/2 safety and imaging analyses.
Positive
- None.
Negative
- None.
News Market Reaction – OCGN
In the Jul 1 session, OCGN declined 3.27%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Conference participation | Neutral | -2.2% | Announced June 2026 investor and industry conference presentations and webcast availability. |
| May 14 | Convertible notes closing | Neutral | -4.8% | Closed $130.0M 6.75% convertible senior notes due 2034 with over-allotment. |
| May 13 | Conference participation | Neutral | +0.0% | Outlined May 2026 scientific and investor conferences for modifier gene therapy platform. |
| May 05 | Earnings and update | Neutral | -19.5% | Reported Q1 2026 results, OCU410 clinical data, and prior $115M convertible notes financing. |
| May 05 | Convertible notes pricing | Neutral | -19.5% | Priced $115M 6.75% convertible senior notes due 2034 in Rule 144A offering. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
modifier gene therapy medical
regenerative approaches in retinal disease medical
phase 2 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026.
Piper Sandler Virtual Ophthalmology Day – Fireside Chat
Date: Friday, July 10, 2026
Time: 10:00–10:25 a.m. EDT
Speaker: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen
Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co.
OIS (Ophthalmology Innovation Source) Retina Innovation Summit
Location: DoubleTree Montreal
Date: Tuesday, July 14, 2026
1:45 p.m. EDT – Regenerative Approaches in Retinal Disease: From Genetic Repair to Functional Restoration
Panelists: Sally Tucker, Peter Francis, Shankar Musunuri, Dhaval Desai, Dina Akasheh, Thomas Ciulla
ASRS (American Society of Retina Specialists)
Location: Palais des Congrès de Montréal
Date: Friday, July 17, 2026
8:21–8:24 a.m. EDT – OCU410 Phase 2 ArMaDa 1-Year Results
Presenter: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research and Director of Fellowship, Sierra Eye Associates; Clinical Professor, University of Nevada, Reno School of Medicine
8:24–8:27 a.m. EDT – Phase 1/2 OCU410 Quantitative FAF/SD-OCT Analysis and Safety Outcomes
Presenter: Jay Chhablani, MD, Professor, University of Pittsburgh and UPMC Vision Institute; President, NetraMind
A webcast of the Piper Sandler presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
